Multiple mechanisms underlie resistance of leukemia cells to Apo2 Ligand/TRAIL.


Targeting death receptors with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has the remarkable potential to selectively kill malignant cells whereas normal cells are largely unaffected by this treatment. However, some tumor cells, including leukemia cells, exhibit resistance to this molecule. To investigate the basis for resistance of… (More)


5 Figures and Tables

Slides referencing similar topics